Abstract

We have developed a new method, the TarSeer™ BRETSA™ Target Engagement System that builds on our existing NanoBRET platform for measuring target engagement to challenging targets in live cells without the need for existing chemical probes. Here, instead of using probe displacement, we are measuring target engagement as a change in protein thermal stability. Doing so provides the possibility of identifying new hits for difficult targets for which there is no existing chemical equity or well defined binding pocket. Furthermore, users of BRETSA do not need to pay licensing fees and instead, BRETSA will be delivered as a reagent.

Speaker

Andrew Zhang, Ph.D.
Director, Pharma/Biotech Market Segment, Promega Corporation

Andrew Zhang serves as a liaison between Promega's products and R&D organization and its customers, identifying mission-critical unmet needs and tailoring solutions accordingly. Prior to joining Promega, he spent 11 years at AstraZeneca, most recently as Head of Chemical Biology. He trained at the interface of small-molecule and antibody-based research, including ADCs, giving him broad perspective across small molecule/TPD and antibody bioassay development. He received his Ph.D. from Yale University.